ArticleOncology letters2026
Dynamic curve type serves as an effective tool for the diagnosis of benign or malignant non-mass enhancements on breast MRI.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identifying malignant non-mass enhancement (NME) in contrast-enhanced breast magnetic resonance imaging (MRI) remains a notable diagnostic challenge due to overlapping imaging features between benign and malignant lesions. Although the delayed-phase kinetic patterns are well-established, the diagnostic value of the initial-phase kinetics has not been fully elucidated. The present study aimed to evaluate the dynamic and morphological characteristics of NME lesions, to determine whether incorporating initial-phase kinetics with delayed-phase analysis improves the discrimination between benign and malignant cases. A prospective study was conducted at the Oncology Teaching Hospital (Baghdad, Iraq) from April to December 2022, including patients referred for breast MRI. Only cases with pure NME (without associated mass lesions) were included. A core biopsy was performed for all cases, with excisional biopsy when indicated. Data collection followed the Breast Imaging Reporting and Data System 5th edition criteria. Among 38 enrolled patients (mean age, 45±11.45 years; range, 26-75 years; median, 44 years), 63.2% presented with a breast lump and 26.3% underwent screening. Histopathology confirmed malignancy in 26 cases (68.4%), comprising 12 cases of ductal carcinoma
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.